Danaher to Acquire Masimo in Transaction Valued at $9.9 Billion
Danaher Corporation has entered into a definitive agreement to acquire Masimo Corporation for $180 per share in cash, valuing the transaction at approximately $9.9 billion. Masimo, known for its pulse oximetry and patient monitoring technologies, will operate as a standalone company within Danaher’s Diagnostics segment upon closing. The acquisition is expected to enhance Danaher’s diagnostic capabilities and generate over $530 million in EBITDA for Masimo by 2027.
Masimo's Board Backs Danaher's $9.9B Cash Acquisition Proposal
Masimo's board has unanimously approved a definitive agreement to be acquired by Danaher for $9.9 billion in cash, with Danaher offering $180 per Masimo share. The acquisition is expected to close in the second half of 2026 and will see Masimo operate as a standalone unit within Danaher’s Diagnostics segment, enhancing Danaher's acute care portfolio. This deal follows a period where Masimo explored various opportunities, including a significant drop in share price after controversial acquisitions and an ongoing patent lawsuit with Apple.
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Masimo Corporation - MASI
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Masimo Corporation (NasdaqGS: MASI) to Danaher Corporation (NYSE: DHR) for $180.00 per share in cash. The law firm is examining whether this consideration and the process leading to the transaction adequately value Masimo. Shareholders who believe the Company is undervalued are encouraged to contact KSF to discuss their legal rights.
Masimo Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Masimo Corporation - MASI
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Masimo Corporation to Danaher Corporation for $180.00 cash per share. KSF aims to determine if this price and the sale process are adequate or if the company is undervalued. The law firm is inviting Masimo shareholders to contact them to discuss their legal rights regarding the proposed transaction.
This Masimo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts have changed their outlook on several companies, resulting in five downgrades for Wednesday. Masimo Corp (NASDAQ: MASI) was downgraded from Buy to Neutral by a BTIG analyst, while Toro Co (NYSE: TTC) was downgraded from Outperform to Market Perform by a Raymond James analyst. Other companies receiving downgrades include Genuine Parts Co (NYSE: GPC), AtriCure Inc (NASDAQ: ATRC), and Transocean LTD (NYSE: RIG).
Danaher buys patient monitoring specialist Masimo in $9.9B deal
Danaher Corporation has announced the acquisition of Masimo, a patient monitoring medtech company, for $9.9 billion. Masimo will operate as a standalone company within Danaher's diagnostics segment, strengthening Danaher's portfolio with advanced sensor technology and AI-enabled monitoring. This acquisition follows a period of challenges for Masimo, including a proxy fight and a legal battle with Apple over patent infringement, and is expected to accelerate growth for Danaher’s diagnostics segment.
Masimo (MASI) Climbs 34% on $9.9-Billion Danaher Merger
Masimo Corporation (MASI) saw its shares jump over 34% after announcing a definitive agreement to be acquired by Danaher Corporation for $9.9 billion, or $180 per share. The acquisition price represents a 38.3% premium over Masimo's closing price on February 13. Masimo will continue to operate as a standalone business unit within Danaher’s Diagnostics segment upon the transaction's expected closing in the second half of the year.
Danaher Corp to acquire Masimo for $9.9B
Danaher Corp announced its acquisition of Masimo Corp for $9.9 billion, including debt, at $180 per share. This move aims to strengthen Danaher's diagnostics portfolio with Masimo's leadership in pulse oximetry and patient monitoring solutions. The acquisition is expected to be accretive to Danaher’s earnings and generate significant synergies, with the transaction anticipated to close in the second half of 2026.
Masimo to Be Acquired by Danaher in $180-Per-Share All-Cash Merger
Masimo announced it will be acquired by Danaher for $180.00 per share in an all-cash merger, making Masimo a wholly-owned subsidiary. The transaction requires Masimo stockholder approval, regulatory clearances, and other conditions, with Politan Capital Management already agreeing to vote its shares in favor. Upon completion, Masimo shares will be delisted from Nasdaq.
Danaher Deal Finalized: Company To Acquire Masimo For $9.9 Billion In Cash
Danaher Corporation has finalized a deal to acquire Masimo Corporation for $9.9 billion in an all-cash transaction, paying $180 per share. This acquisition is expected to strengthen Danaher's Diagnostics segment, adding to its adjusted earnings per share and allowing Masimo to operate as a standalone business within Danaher. The deal, anticipated to close in the second half of 2026, aims to deliver strategic growth, financial benefits, and significant synergies.
Danaher Agrees to Buy Medical Tech Firm Masimo for $9.9 Billion
Danaher Corp. has agreed to acquire medical technology firm Masimo Corp. for approximately $9.9 billion, paying $180 per share in cash. This acquisition, which represents a nearly 40% premium over Masimo's closing share price on Friday, will allow Danaher to expand its presence in the medical supply business. The deal is anticipated to close in the second half of the current year.
S&P 500 Futures Fall in Premarket Trading; Masimo, Enlight Renewable Energy Lead
S&P 500 futures are down in premarket trading. Masimo Corp. (MASI) saw a significant premarket gain of 34.5%, while Enlight Renewable Energy Ltd. (ENLT) rose by 8.0%. These movements come ahead of the U.S. stock market opening in two hours.
ING Groep NV Buys New Position in Masimo Corporation $MASI
ING Groep NV has acquired a new position in Masimo Corporation (NASDAQ:MASI) during the third quarter, purchasing 20,800 shares valued at approximately $3.07 million. Other institutional investors have also adjusted their holdings, with hedge funds and institutions collectively owning 85.96% of the company's stock. Masimo opened at $130.15, has a market cap of $6.99 billion, and analysts currently have a "Hold" rating on the stock with a consensus price target of $189.40.
Halper Sadeh LLC Encourages Masimo Corporation Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether Masimo Corporation (NASDAQ: MASI) officers and directors breached their fiduciary duties to shareholders. The firm encourages long-term shareholders to contact them to discuss potential legal rights and options, including corporate governance reforms or financial incentives. Halper Sadeh LLC operates on a contingent fee basis, meaning no out-of-pocket payment for legal fees from participants.
Masimo sets Feb. 26 date to reveal 2025 earnings numbers
Masimo (NASDAQ: MASI) will announce its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, after the market closes. The company will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results, led by CEO Katie Szyman and CFO Micah Young. Masimo is a global medical technology company known for its monitoring technologies and patient safety solutions.
Here's Why You Should Add Masimo Stock to Your Portfolio Now
Masimo Corporation (MASI) is positioned for growth due to strong demand for its innovative technology, R&D efforts, and solid Q3 2025 performance. The company has outlined a long-term strategy for revenue growth, improved margins, and strong cash flow, with projected revenues of $1.52 billion for 2025. Despite concerns about tariff pressure and capital equipment volatility, Masimo's strategic alliances and focus on intelligent patient monitoring are expected to drive future success.
Masimo Corporation (NASDAQ:MASI) Given Average Rating of "Hold" by Analysts
Analysts have issued a consensus "Hold" rating for Masimo Corporation (NASDAQ:MASI), based on reports from eight firms, with an average one-year target price of $189.40. The company recently exceeded quarterly EPS estimates and reported an 8.2% year-over-year revenue increase. Shares opened at $136.62, and Masimo specializes in noninvasive monitoring solutions and medical technology.
Here's Why You Should Add Masimo Stock to Your Portfolio Now
Masimo Corporation (MASI) is positioned for growth due to strong demand for its technology, R&D efforts, a solid third-quarter 2025 performance, and a robust product portfolio, despite concerns about overdependence on its Signal Extraction Technology (SET) unit and reimbursement headwinds. The company has outlined long-term growth strategies and financial targets through 2028, focusing on revenue growth, improved margins, and strong cash flow, with strategic alliances and intelligent patient monitoring advancements driving its prospects. While tariff pressures on gross margins and volatile capital equipment growth are noted as potential downsides, analysts show a positive estimate revision trend for 2026 earnings.
Great Lakes Advisors LLC Sells 80,971 Shares of Masimo Corporation $MASI
Great Lakes Advisors LLC significantly reduced its stake in Masimo Corporation, selling 80,971 shares in the third quarter, decreasing its holdings by 98.3% to only 1,377 shares. Despite this sell-off, several other institutional investors, such as Massachusetts Financial Services Co., increased their positions, with institutional investors collectively owning approximately 85.96% of the company. Masimo reported strong quarterly earnings of $1.32 EPS and 8.2% revenue growth, leading to a consensus "Hold" rating from analysts with an average price target of $189.40.
Masimo EVP Anand sells $2.56 million in shares By Investing.com
Masimo's Executive Vice President, Sampath Anand, sold 12,180 shares of common stock for approximately $2.56 million on January 28, 2026, transactions that also involved the exercise of stock options. Despite this insider selling, InvestingPro data indicates aggressive share buybacks by management. The company recently announced strong preliminary financial results for 2025 and provided positive long-term growth targets, with several analysts maintaining or raising their price targets, while others reiterated a Hold rating.
Masimo EVP Anand sells $2.56 million in shares By Investing.com
Masimo's Executive Vice President, Sampath Anand, sold 12,180 shares of common stock for approximately $2.56 million on January 28, 2026, after exercising options for 30,000 shares. Despite this insider selling, management has been actively buying back shares. The company recently projected a 9% increase in full-year revenue for 2025 and an anticipated 12% Q4 growth, with analysts maintaining positive ratings and setting higher price targets for Masimo.
Owlet vs. Masimo: Which Medical Monitoring Stock Is the Better Buy?
This article compares Owlet (OWLT) and Masimo (MASI), two medical monitoring companies, to determine which stock is a better investment. Owlet is presented as a growth-oriented pediatric health company transitioning to a subscription model, while Masimo is an established leader in hospital monitoring focusing on core healthcare operations. Despite their differences, both are benefiting from increased regulatory scrutiny and continuous monitoring trends.
Why Masimo (MASI) is Poised to Beat Earnings Estimates Again
Masimo (MASI) is expected to beat its upcoming earnings estimates, continuing a strong streak from prior quarters. The company's positive Zacks Earnings ESP of +8.04% combined with a Zacks Rank #2 (Buy) suggests a high probability of another earnings surprise. Masimo has a history of exceeding earnings expectations, and its next earnings report is anticipated on February 26, 2026.
Strs Ohio Reduces Stock Position in Masimo Corporation $MASI
Strs Ohio has significantly reduced its stake in Masimo Corporation, selling 34.1% of its holdings, which amounted to 19,070 shares. Despite this reduction, Masimo (NASDAQ:MASI) exceeded quarterly earnings expectations and provided optimistic FY2025 guidance. The company maintains a "Hold" consensus rating from analysts, with a target price of $189.40, while many institutional investors increased their positions in the medical equipment provider.
Wall Street Analysts Think Masimo (MASI) Could Surge 31.06%: Read This Before Placing a Bet
Wall Street analysts project Masimo (MASI) could see a 31.06% surge based on an average price target of $183.75, with estimates ranging from $162.00 to $210.00. While price targets should be viewed with skepticism due to potential analyst optimism, Masimo's Zacks Rank #2 (Buy) and positive earnings estimate revisions suggest a legitimate upside. Investors are advised to consider these factors alongside the consensus price target.
Masimo wants Apple’s bid to erase a $634 million patent-infringement verdict overturned
Masimo Corp. has urged a California federal judge to reject Apple's attempt to overturn a $634 million patent-infringement verdict related to Apple Watch heart-rate alerts. Masimo argues that sufficient trial evidence supported the damages award, pointing to doctor's statements, Apple's marketing, and expert testimony. This development is part of an ongoing legal battle where Masimo claims Apple infringed on its blood oxygen-sensing technology patents and stole trade secrets and employees.
Masimo to Sell Consumer Audio Business to HARMAN for $350 Million
Masimo has announced its decision to sell its Sound United consumer audio division, which includes brands like Bowers & Wilkins, Denon, Marantz, and Polk Audio, to HARMAN International for $350 million. This strategic move aims to refocus Masimo on its core professional healthcare business, while HARMAN will expand its audio portfolio. The transaction is expected to finalize by the end of 2025, pending regulatory approvals.
Massachusetts Financial Services Co. MA Boosts Holdings in Masimo Corporation $MASI
Massachusetts Financial Services Co. MA increased its stake in Masimo Corporation (NASDAQ:MASI) by 6.1% in the third quarter of 2025, now owning 2,619,960 shares valued at approximately $386.6 million. Masimo exceeded Q3 earnings estimates with $1.32 EPS and $371.2 million in revenue, setting a FY2025 guidance of $5.62–$5.79 EPS. Despite a consensus "Hold" rating from Wall Street analysts, institutional investors collectively own about 85.96% of the company's stock.
Sumitomo Mitsui Trust Group Inc. Trims Stock Position in Masimo Corporation $MASI
Sumitomo Mitsui Trust Group Inc. reduced its stake in Masimo Corporation by 15.7% in the third quarter, now owning 397,248 shares valued at approximately $58.6 million. Despite overall mixed analyst ratings, Masimo surpassed Q3 earnings and revenue estimates and provided positive FY2025 EPS guidance, although it reported a negative net margin. Other institutional investors also adjusted their positions in the medical equipment provider.
Masimo (NASDAQ:MASI) Updates Q4 2025 Earnings Guidance
Masimo (NASDAQ:MASI) updated its Q4 2025 earnings guidance, projecting higher EPS and revenue than analysts' consensus. Despite the positive guidance, the stock experienced a slight intraday dip. The company also set its FY2025 EPS guidance above analyst expectations and recently reported its previous quarter's results.
Masimo Corporation (MASI) Stock Analysis: Exploring a 32% Potential Upside in the Healthcare Sector
Masimo Corporation (MASI), a healthcare sector player known for its medical devices, shows a potential upside of 32.27% according to analysts. Despite some profitability challenges indicated by a negative EPS and ROE, the company boasts a strong free cash flow of $329.1 million and positive analyst sentiment with no sell ratings. Technical indicators suggest a potential buying opportunity for investors looking for growth in medical devices.
Masimo Releases Preliminary Q4 Results
Masimo Corp. announced its preliminary financial results for the fourth quarter and full year, expecting a 12% increase in Q4 revenue to $411 million and a 9% growth in full-year revenue to $1.5 billion. Despite exceeding analyst expectations, the company's shares fell 4% to $133.35. Complete financial results are slated for release on February 26.
Masimo Corporation (NASDAQ:MASI) Receives Consensus Rating of "Hold" from Analysts
Eight brokerages currently cover Masimo Corporation (NASDAQ:MASI), resulting in a consensus "Hold" rating, with an average 12-month target price of $189.40. Institutional investors own a significant 85.96% of the company's stock, with major firms like Vanguard and State Street increasing their positions. The company's shares are trading below their 52-week high, and while it has a negative trailing P/E, analysts expect positive earnings per share for the current fiscal year.
How to watch Masimo’s talk at the J.P. Morgan 2026 healthcare event
Masimo (NASDAQ: MASI) announced it will participate in the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14, 2026, at 2:15 p.m. Pacific time. A live webcast of the presentation will be available on the Masimo website, with a replay accessible afterward. Masimo is a global medical technology company focused on improving patient outcomes through innovative monitoring technologies.
Here's Why You Should Retain Masimo Stock in Your Portfolio Now
Masimo Corporation is expected to see continued growth due to strong demand for its innovative technology and ongoing R&D efforts, reinforced by a solid third-quarter 2025 performance and product portfolio. Despite concerns about overreliance on its SET unit and reimbursement challenges, the company has consistently surpassed earnings estimates. Strategic partnerships and advancements in intelligent monitoring and wearables are key drivers for future growth.
Apple's Rival Masimo Tumbles In Quality Despite $634 Million Patent Win Over iPhone-Maker
Despite a significant $634 million patent infringement win against Apple Inc., Masimo Corp. is showing "warning signals" in its underlying fundamentals, according to Benzinga Edge's Stock Rankings data. The company's quality score has reportedly dropped to 10.43, indicating poor operational efficiency and financial health compared to peers, and its momentum score is also low, pointing to weak stock performance. This decline in quality comes despite the legal victory over Apple regarding blood-oxygen sensor patents used in the Apple Watch.
Masimo Corporation $MASI Shares Sold by Voya Investment Management LLC
Voya Investment Management LLC significantly reduced its stake in Masimo Corporation, selling 75.1% of its holdings in Q3, leaving it with 4,876 shares worth $719,000. Despite this, institutional investors still own 85.96% of the company, which is currently trading near its 52-week low with a "Hold" consensus rating from analysts. Masimo, a medical technology company, specializes in noninvasive monitoring solutions and reported $1.42 EPS for the last quarter.
Wells Fargo Maintains Overweight on Masimo (MASI) Following Investor Day Confidence In Long-Range Revenue Targets
Wells Fargo and BTIG have maintained Overweight and Buy ratings, respectively, on Masimo (NASDAQ: MASI) following the company's Investor Day. Both firms expressed confidence in Masimo's long-range revenue targets and commitment to R&D, projecting sustained multi-year growth and positioning it as a top-tier MedTech performer. The company reported strong Q3 2025 results with increased revenue and adjusted EPS, and raised its full-year 2025 guidance.
Masimo Corporation stock hits 52-week low at 131.47 USD
Masimo Corporation's stock has reached a 52-week low at $131.47, reflecting a challenging year with a 22.35% decline over the past 12 months. Despite not being profitable in the last year, analysts predict profitability for the company this year with an EPS forecast of $5.55, and six analysts have revised their earnings expectations upward. Strategic initiatives discussed at Investor Day, including revenue CAGR targets and revised EPS, suggest potential future growth.
Masimo Corporation $MASI Shares Sold by Perpetual Ltd
Perpetual Ltd significantly reduced its stake in Masimo Corporation, selling 49.7% of its holdings in Q3, bringing its total to 10,648 shares valued at approximately $1.57 million. Despite this, institutional ownership remains high at 85.96%, with other major funds increasing their positions. Analyst sentiment is mixed, resulting in a consensus "Hold" rating and a target price of $189.40 for Masimo (NASDAQ:MASI).
Masimo stock hits 52-week low at 133.66 USD
Masimo Corporation's stock has hit a 52-week low of $133.66, marking a 22.49% decline over the past year due to various market challenges. Despite this, the company maintains strong liquidity and analysts have revised earnings upwards, with several firms reiterating positive ratings and price targets based on long-term growth strategies presented at their Investor Day. Investors are monitoring Masimo's ability to rebound from this low point.
Masimo Corporation $MASI Shares Sold by Texas Permanent School Fund Corp
The Texas Permanent School Fund Corp significantly reduced its stake in Masimo Corporation, selling over 17,000 shares and retaining a holding valued at $5.793 million. Despite this, other major institutions like Massachusetts Financial Services and Westfield Capital increased their positions, indicating mixed investor sentiment. Masimo shares are currently trading near their 1-year low, with analysts providing a mixed outlook but an average price target significantly higher than current prices.
Corient Private Wealth LLC Sells 17,624 Shares of Masimo Corporation $MASI
Corient Private Wealth LLC reduced its stake in Masimo Corporation (NASDAQ:MASI) by 5.1% in the second quarter, selling 17,624 shares and now owning 330,414 shares worth $55.58 million. Other institutional investors like Nordea Investment Management AB and Westfield Capital Management Co. LP also adjusted their positions. Masimo's stock opened at $134.52, has a market capitalization of $7.23 billion, and analysts have a consensus "Hold" rating with an average target price of $189.40.
Masimo stock hits 52-week low at 133.66 USD By Investing.com
Masimo Corporation's stock has reached a 52-week low at $133.66, marking a 22.49% decline over the past year due to various market challenges. Despite this, InvestingPro data indicates aggressive share buybacks by management and upward revised earnings forecasts from analysts. The company, which is not currently profitable, maintains strong liquidity and appears slightly undervalued.
Masimo Corporation $MASI Shares Purchased by Bellevue Group AG
Bellevue Group AG increased its stake in Masimo Corporation by 28.5% during the second quarter, bringing its total holdings to 89,673 shares. This move is part of broader institutional investor activity, with several other firms also modifying their positions in the medical equipment provider. Masimo's stock is currently trading down 2.1%, and analysts have issued varied ratings and price targets, with a consensus "Hold" rating.
Russell Investments Group Ltd. Trims Stock Position in Masimo Corporation $MASI
Russell Investments Group Ltd. reduced its stake in Masimo Corporation by 68.5% in Q2, selling 23,812 shares and retaining 10,935 shares valued at $1.84 million. Conversely, other institutional investors like American Century Companies Inc. and XTX Topco Ltd increased their positions significantly. Despite mixed analyst ratings with a "Hold" consensus and an average price target of $189.40, the stock has a negative net margin and P/E ratio, trading near $139.77.
Norges Bank Acquires New Stake in Masimo Corporation $MASI
Norges Bank has acquired a new stake in Masimo Corporation (NASDAQ:MASI) during the second quarter, purchasing 39,053 shares valued at approximately $6,569,000. This acquisition makes Norges Bank the owner of about 0.07% of Masimo. Other institutional investors have also adjusted their holdings, with Masimo's stock showing a market capitalization of $7.45 billion and a consensus "Hold" rating from analysts.
Patient Monitoring Stocks Q3 Recap: Benchmarking Masimo (NASDAQ:MASI)
This article reviews the Q3 performance of patient monitoring stocks, focusing on Masimo (NASDAQ:MASI) and its peers. It highlights the sector's growth drivers like chronic disease prevalence and digital health adoption, alongside challenges such as high R&D costs and regulatory hurdles. The report details Masimo's strong quarter, iRhythm's exceptional performance, and ResMed's weaker results, while also providing updates on DexCom and Insulet.
HALPER SADEH LLC ENCOURAGES MASIMO CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Masimo Corporation (NASDAQ: MASI) breached their fiduciary duties to shareholders. The firm encourages long-term Masimo shareholders to contact them to discuss potential corporate governance reforms, the return of funds to the company, or other relief. Shareholder involvement is highlighted as crucial for improving company policies and enhancing shareholder value.
Masimo Pitches 2028 Plan With 30% Operating Margins
Masimo Corporation (NASDAQ: MASI) outlined its long-term strategy and financial projections through 2028 at its Investor Day, targeting a 7-10% revenue CAGR and 30% operating margins. The company aims for $8.00 adjusted EPS by 2028 and reaffirms its 2025 guidance. This update follows a recent legal victory against Apple and strong third-quarter earnings.
